MedTrace Logo

Relative Bioavailability and Food Effect of SYHA1813 Oral Solution in Healthy Participants

NCT06157918 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2024-11-08

No results posted yet for this study

Summary

This is a three-period crossover phase I study designed to evaluate the relative bioavailability, food effect, safety and tolerability of SYHA1813 oral solution in healthy participants.

Conditions

  • Healthy Participants

Interventions

DRUG

SYHA1813 oral solution (2.0g:25mg)

SYHA1813 oral solution, 25mg, oral

DRUG

SYHA1813 oral solution (20ml:200mg)

SYHA1813 oral solution, 25mg, oral

Sponsors & Collaborators

  • Shanghai Runshi Pharmaceutical Technology Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-20
Primary Completion
2024-01-26
Completion
2024-01-26

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06157918 on ClinicalTrials.gov